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EDITORIALS 
Angiotensin-Converting Inhibitors in Patients 
with Congestive Heart Failure: A Class Effect? 
Bertram Pitt, MD 
A 
ngiotensin-converting enzyme (ACE) inhibi- 
tors have been shown to improve exercise per- 
formance, patient well-being and survival in 
patients with heart failure. l-4 Both captopril and enala- 
pril have been approved for use in heart failure and it is 
likely that several other ACE inhibitors will be ap- 
proved within the near future. Although they differ in 
duration of action and side-effect profile, it has general- 
ly been thought that one ACE inhibitor is equal to an- 
other in effcctiveness.5 This concept has now been chal- 
lenged by Pouleur et a1,6 who found in a retrospective 
analysis of baseline therapy in the Xamoterol Mortality 
Trial that patients receiving baseline therapy with cap- 
topril had a significantly higher mortality than those 
receiving enalapril. 
Pouleur et al postulate that the higher mortality of 
patients receiving captopril in their study was due to the 
fact that captopril’s duration of action is shorter than 
that of enalapril. Because captopril is recommended to 
be used 3 times daily, compared with 2 times daily for 
enalapril in patients with heart failure, compliance may 
have been worse with captopril, thereby leaving patients 
exposed to the adverse effects of rerun-angiotensin sys- 
tem activation. Furthermore, many investigators in 
their study administered captopril at a lower than rec- 
ommended dose or on a twice-daily rather than a three- 
times daily schedule in order to reduce the cost of 
chronic therapy. However, one should be skeptical of 
any retrospective analysis such as that performed by 
Pouleur et al. Their trial was not designed, nor statisti- 
cally empowered, to explore the relative difference in 
effectiveness between captopril and enalapril. Neverthe- 
less, one cannot ignore the possibility that significant 
differences in the effectiveness of various ACE inhibi- 
tors might exist. 
If differences in the effectiveness of ACE inhibitors 
do exist, how might they be explained? One explana- 
tion is that proposed by Pouleur et a1.6 Should the 
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neuroendocrine hypothesis for heart failure prove to be 
valid-i.e., that activation of neurohormones, in partic- 
ular the renin-angiotensin system, is important in deter- 
mining survival in patients with heart failure-one 
could postulate that failure to provide adequate and 
continuous blockade of the renin-angiotensin system 
could lead to an increase in the incidence of manifest 
heart failure and death. In the Cooperative North 
Scandinavian Enalapril Survival Study (CONSEN- 
SUS) trial of enalapril in patients with class IV heart 
failure, Swedberg et al7 showed that enalapril was ef- 
fective in reducing the incidence of progressive heart 
failure and mortality only in patients with marked 
activation of the renin-angiotensin system. The Veter- 
ans Administration Vasodilator Heart Failure Trial-II 
(VHEFT-II) comparing a strategy of direct-acting va- 
sodilators with isosorbide dinitrate-hydralazine to an 
ACE inhibitor strategy with enalapril has shown that 
enalapril was more effective in reducing mortality 
(Cohn J, personal communication). The reduction in 
mortality with enalapril in the VHEFT-II occurred de- 
spite the fact that the isosorbide dinitrate-hydralazine 
combination appeared to be the more effective vasodila- 
tor, as evidenced by a greater improvement in left ven- 
tricular ejection fraction and exercise performance. The 
improved mortality with enalapril in both the CON- 
SENSUS trial and the VHEFT-II is therefore likely 
due to the fact that it is an inhibitor of the renin-angio- 
tensin system rather than a pure vasodilator. 
Other explanations for a potential difference in the 
efficacy of captopril and enalapril can also be postu- 
lated. Toussaint et al8 showed in a study of human vol- 
unteers that there may be significant differences in the 
effectiveness of loop diuretic-induced natriuresis with 
different ACE inhibitors. They compared the natriuret- 
ic effect of furosemide alone and after pretreatment 
with 3 ACE inhibitors: 100 mg of captopril, 5 and 10 
mg of ramapril, and 20 mg of enalapril by mouth. In 
those pretreated with captopril, there was significantly 
less natriuresis than with ramapril or enalapril. They 
found that captopril interfered with the delivery of furo- 
semide to the distal renal tubule and, hence, natriuresis. 
In patients with heart failure, a relative decrease in ef- 
fective diuresis and natriuresis with 1 ACE inhibitor 
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versus another could lead to a higher incidence of salt 
and water retention, manifest heart failure, and further 
activation of neurohormones, thereby leading to the 
well-known vicious cycle of heart failure. Although 
their study needs to be confirmed and repeated in pa- 
tients with heart failure, it does raise the possibility that 
there may be important differences among the various 
ACE inhibitors. 
The possibility that the major effects of ACE inhibi- 
tors may not be through blockade of the serum angio- 
tensin system, but rather through the tissue ACE sys- 
tem is even more intriguing.9-1 l The tissue ACE system 
has important effects on vascular and myocardial re- 
modeling. Differences in lipophilicity and chemical 
structure among the various ACE inhibitors results in 
differential effectiveness in inhibiting ACE activity, in 
particular tissues and organs.9-11 Whether or not the 
differential effects of various ACE inhibitors in specific 
organ systems are of importance needs to be deter- 
mined by appropriate, prospective, well-controlled com- 
parative studies. 
There are also other differences that need to be con- 
sidered relative to the clinical effectiveness of various 
ACE inhibitors. Captopril has, in contrast to enalapril, 
a sulfhydryl (SH) group. Although this was originally 
thought to be a disadvantage due to the side effects 
inherent to the SH group, recent studies have suggested 
that the SH group could be an asset. Captopril prevents 
the oxidation of catecholamines and has been shown to 
be more effective than enalapril in protecting against 
myocardial stunning. l l-l 4 
What can the clinician infer from the study of Pou- 
leur et al? First, I believe that we should continue to 
use both captopril and enalapril for heart failure thera- 
py. Both have been shown to reduce the incidence of 
manifest heart failure and its consequences.1-4J5 Cap- 
topril should, however, be prescribed only as recom- 
mended in the package insert, 3 times daily. The clini- 
cian should be wary of using any new ACE inhibitor or 
vasodilator in patients with heart failure based solely on 
evidence of benefit in another indication, such as hyper- 
tension, or comparability in improving exercise perfor- 
mance. Approval for use of an ACE inhibitor or vaso- 
dilator should not, in my opinion, be based on demon- 
stration of an improvement in exercise performance 
alone without demonstration of a reduction in the inci- 
dence of manifest heart failure, if not mortality. Our 
knowledge of the pathophysiology of heart failure is as 
yet incomplete, The use of surrogate end points, such as 
exercise performance, which appear to depend on vaso- 
dilation for approval and clinical use of ACE inhibitors, 
although convenient, may not be just&d. Although we 
want our patients to feel better and to exercise more, 
we also need to know that we can prevent the develop- 
ment of manifest heart failure, with all of its deleterious 
consequences and costs. Prevention of the development 
of manifest heart failure and improvement of survival 
may depend on completeness in blockade of the serum 
or the tissue renin angiotensin system, or both. Until we 
have greater understanding of these effects, it would be 
prudent to prescribe only ACE inhibitors that have 
been shown to prevent the development of manifest 
heart failure or improve survival, or both, and only in 
doses shown to be effective in the pivotal trials. 
Before new ACE inhibitors or vasodilators are ap- 
proved for use in heart failure, we need to have more 
data on the effective as well as the minimally effective 
dose. We still do not know the minimally effective dose 
of captopril or enalapril for preventing manifest heart 
failure and death. This may or may not be the same 
dose that blocks the serum renin-angiotensin system. If 
Poleur et al6 are correct, many of our patients currently 
treated with ACE inhibitors may not be adequately 
protected. 
The concept of class effectiveness is being chal- 
lenged not only for ACE inhibitors, but also for @-adre- 
nergic blocking agents. A recent study by Ablad et all6 
suggests that lipophilic P-adrenergic blockers might be 
more effective than hydrophilic p blockers in reducing 
sudden cardiac death.16 Although both lipophilic and 
hydrophilic P-adrenergic blocking agents were equally 
effective in reducing heart rate and evidence of isch- 
emia in their animal model, the lipophilic p blocker was 
more effective in reducing sudden death by increasing 
central vagal tone. 
We need well-controlled, prospective, comparative 
trials to determine whether or not claims of class effec- 
tiveness are valid. It is possible that we may need to 
reevaluate our current concepts of class effectiveness in 
the light of new understanding of pathophysiology. 
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Permanent Pacing as Treatment for 
Hypertrophic Cardiomyopathy 
Kenneth M. McDonald, MB, MRCPI, and Brian Maurer, FRCPI, FESC 
T 
he management of patients with hypekrophic 
cardiomyopathy (HC) is directed at 2 separate 
but interrelated goals: the amelioration of symp- 
toms and the identification of those patients at risk of 
sudden cardiac death. Symptomatic improvement can 
be obtained in most patients with the use of standard 
pharmacotherapy.lF3 Surgical intervention, either in the 
form of septal myectomy or mitral valve replacement, 
can be considered for those with obstructive disease 
who do not respond to medical therapy.3- 5 Septal 
myectomy and mitral valve replacement are successful 
procedures that lessen both the resting and provokable 
outflow tract gradient, reduce left ventricular end-dia- 
stolic pressure and result in significant symptomatic im- 
provement.4J 
Unfortunately all of these treatments have disadvan- 
tages. Calcium antagonists are associated with major 
and minor side effects.6 Verapamil may precipitate pul- 
monary edema, especially in patients with signilicant 
resting outflow tract gradients and a high left ventricu- 
lar end-diastolic pressure. 6 Beta blockers in the doses 
prescribed often cau.se fatigue. Both groups of drugs 
may precipitate conduction disturbances.6 Surgical 
myectomy and mitral valve replacement, although suc- 
cessful in relieving symptoms, have an operative mor- 
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tality ranging from 3 to 16% and have not been shown 
to alter the natural history of this disease.7>8 
Because of these difficulties, it is important to 
search for alternative management options, especially 
for patients with HC who are refractory to the afore- 
mentioned standard therapy. Several centers, including 
our own, have pioneered the use of atrioventricular 
sequential pacing in the management of these pa- 
tients.9-16 Pacing in these circumstances is being used 
to relieve symptoms and not to manage conduction sys- 
tem disease. 
Hassenstein et aI9 were the first to describe this ap- 
proach. They reported a 56% reduction in left ventricu- 
lar outflow tract gradient during paced rhythm in 4 
patients, all of whom reported symptomatic improve- 
ment. These findings were confirmed by Duch et al,” 
who observed similar hemodynamic results in a series 
of 21 patients. Twelve patients in this group had a re- 
duction of ventricular outflow tract gradient of 250% 
in paced rhythm. Only 1 patient did not achieve any 
reduction in gradient in paced rhythm. The reduction 
in gradient was associated with a decrease in left ven- 
tricular filling pressure. These hemodynamic responses 
were not associated with any significant reduction in 
mean arterial pressure. This response mirrors the he- 
modynamic outcome from surgical interventions in this 
condition. Similar findings have been reported by both 
Dupok, lo Gardiner13 and their co-workers. Recently, 
preliminary data from the National Institutes of Health 
have shown a similar favorable hemodynamic and 
symptomatic response with pacing in this condition.16 
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